CRISPR Therapeutics AG — Director's Dealing 2021

Oct 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2021-10-14

Reporting Person: Smith Brendan (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-14	Restricted Stock Units	$	A	15000	Acquired		Common Shares (15000)	Direct
2021-10-14	Stock Option (Right to Buy)	$98.70	A	90000	Acquired	2031-10-14	Common Shares (90000)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2: This restricted stock unit award was granted on October 14, 2021 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on October 14, 2022, (ii) one quarter of the shares vesting on October 14, 2023, (iii) one quarter of the shares vesting on October 14, 2024, and (iv) one quarter of the shares vesting on October 14, 2025.

F3: This option was granted on October 14, 2021 with respect to 90,000 Common Shares, with 25% of the shares vesting on October 14, 2022 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.